A survey from the American Academy of Dermatology found that younger generations lack skin cancer knowledge.
Linda Stocum, Associate Editor
Advertisement
Articles by Linda Stocum, Associate Editor
Deucravacitinib meets primary end points for treating moderate to severe psoriasis.
The FDA has set a Prescription Drug User Fee Act (PDUFA) date for bimekizumab (UCB) for the treatment of psoriasis.
Advertisement
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
